Setback
Vicarious had aimed for first human trials by mid-2025, but in August 2025 it said it would hold off to keep developing the robot.
A delay, pause or setback · Company-reported
What the source says
“Then, in August, the company said Vicarious would hold off on clinical trial initiation to further develop its robot.”
What it means
Vicarious Surgical Robotic System, from Vicarious Surgical, is at stage 1 of 5 on our ladder: demo only. A setback stays on the record next to the milestones; the stage moves down only when the rules say so. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: Our sources report it working without human help.
More on Vicarious Surgical Robotic System
- Shareholders voted to shut Vicarious down and liquidate it at once, and the remaining staff lost their jobs. The company had raised about $300 million in total.
- Vicarious's board asked shareholders to close and sell off the company. It said it could not raise more money or find a buyer.
- The New York Stock Exchange began removing Vicarious's stock because the company's market value had fallen below the minimum.
- Vicarious finished a test operation on pigs, its first animal cases in several years, and set a final design for the end of 2026.
- Vicarious agreed to go public through a $1.1 billion merger with a shell company (a SPAC). Backers included Bill Gates and Khosla Ventures.
- The FDA gave Vicarious's robot breakthrough device designation, a program meant to speed up review. This is not a clearance.